Coloplast (COLO) AGM 2025 summary

Opening remarks and agenda

• Board and management introduced; AGM chairman appointed and meeting confirmed as lawfully convened.

• Agenda covered the board report, annual report, profit allocation, remuneration, proposals, board and auditor elections, and other business.

Financial performance review

• FY2024/25 organic growth was 7%; net revenue was DKK 27,874m, up 3%, and EBIT margin was 28% before special items.

• Operating profit before special items was DKK 7.7bn; gross profit was DKK 18.9bn, with a 68% gross margin.

• Net profit was DKK 3,636m and free cash flow was DKK 5,394m.

• ROIC after tax before special items was 15%.

• 2025/26 outlook: organic growth and EBIT growth each expected at 7%, with ROIC at 16%.

Board and executive committee updates

• Lars Rasmussen served as Interim CEO and did not seek re-election to the Board.

• Jette Nygaard-Andersen, Niels Peter Louis-Hansen, Annette Brüls, Carsten Hellmann and Marianne Wiinholt were re-elected; Niels B. Christiansen was elected.

• After the AGM, Jette Nygaard-Andersen became Chair and Niels Peter Louis-Hansen Deputy Chair; employee-elected directors are Thomas Barfod, Nikolaj Kyhe Gundersen and Roland Vendelbo Pedersen.

• Two business units, Chronic Care and Acute Care, were established to align with the strategy.